Jennifer Dominguez-Pineda, MD

home / authors / jennifer-dominguez-pineda-md

Articles

Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors

Francisco J. Castro-Alonso, MD;Jennifer Dominguez-Pineda, MD;Guillermo Rosales-Sotomayor;Thomas W. Flaig, MD;María T. Bourlon, MD, MSc, FASCO

May 15th 2018

A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.

Published: April 21st 2025 | Updated: April 26th 2025

Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777